Loading clinical trials...
Loading clinical trials...
To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
NCT07494864 · Asymptomatic Bacteriuria in Subjects Not Requiring Assisted Bladder Emptying, Asymptomatic Bacteriuria in Subjects Relying on Some Type of Catheter, and more
NCT03952299 · Overactive Bladder Syndrome, Neuropathic Bladder
NCT04873037 · Overactive Bladder Syndrome, Overactive Bladder, and more
NCT06094543 · Overactive Bladder Syndrome, Urinary Incontinence
NCT07081412 · Overactive Bladder Syndrome, Overactive Bladder (OAB), and more
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Gilbert, Arizona
Pfizer Investigational Site
Gilbert, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions